Skip to main content

Safeguards needed in wake of diluted cancer drugs, says New Brunswick premier

TORONTO — It's unacceptable that more than 1,200 cancer patients received diluted chemotherapy drugs and safeguards are needed to restore confidence in the health-care system, New Brunswick Premier David Alward said Monday.

"We need to make sure that we can give full confidence to the people of New Brunswick or Ontario — or Canada ultimately — that the proper system is in place, so that they can have full confidence in it," he told The Canadian Press.

"We have a very good system. But we can't afford, in any way, to take chances that it's not working the way it's supposed to."

Story continues below advertisement

Alward said he spoke to Ontario Premier Kathleen Wynne about the cancer drug scare when he met with her Monday in Toronto.

"Are people concerned and are we concerned? Absolutely," he said after their meeting in her legislative office.

"That's why I'm very pleased to see how quickly the government of Ontario has moved forward with a decision on the investigation."

The governing Liberals have appointed a pharmacy expert, Jake Thiessen, to review the province's cancer drug system. A working group that includes doctors, Cancer Care Ontario, Health Canada and others are also looking at the issue.

A legislative committee also voted Monday to launch its own investigation into the drug scare immediately.

The committee will look into the apparent lack of oversight, standards and monitoring of companies like Marchese Hospital Solutions, which provided the diluted drugs.

It will also probe Ontario's pharmaceutical regulations and inspection procedures, and what impact the diluted drugs may have had on the patients, which included children.

Story continues below advertisement

Marchese, a Mississauga, Ont.-based company, was contracted to prepare the chemotherapy drugs for four hospitals in Ontario and one in New Brunswick, where about 186 patients received the weaker-than-prescribed drugs.

Too much saline was added to the bags containing cyclophosphamide and gemcitabine, in effect watering down the prescribed drug concentrations by up to 20 per cent. Some patients were given the drugs for up to a year.

But the diluted drugs didn't contribute to the deaths of at least 117 cancer patients at a London, Ont., hospital, said Ontario Health Minister Deb Matthews.

Neil Johnson, vice-president of cancer care at the hospital, said oncologists reviewed the cases and "they are confident that there is no causal link between the underdosing and the deaths," Matthews said in the legislature.

"He's saying it didn't contribute to their deaths," she added.

Ontario's New Democrats say they have their doubts.

Story continues below advertisement

"I'd like to see something definitive and researched-based," said NDP Leader Andrea Horwath.

Marchese said its products weren't defective, and suggested that the problem wasn't how the drugs were prepared but how they were administered at the hospitals.

But there is a gap in the oversight of companies like Marchese that mix drugs for hospitals, which usually do it themselves.

The company falls into a jurisdictional grey area, with both the Ontario College of Pharmacists and Health Canada unable to agree on who was responsible for the facility.

The college oversees pharmacists, including those who may have worked independently for Marchese Hospital Solutions. Health Canada oversees drug manufacturers.

But Marchese wasn't considered a pharmacy or a drug manufacturer.

Story continues below advertisement

Wynne said last week that both Health Canada and the college are working to close that gap, and the college is willing to provide oversight of new compounding facilities like Marchese.

Like Wynne, Alward said he won't tell hospitals to mix their own chemotherapy from now on. It's a decision that should be left up to health-care professionals, he said.

The hospital in New Brunswick that received the watered down chemotherapy drugs has already gone back to preparing its own.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter